NHU(SZ:002001)2024-04-22 14:41Financial Performance - The company's operating revenue for 2023 was ¥15,116,537,003.30, a decrease of 5.13% compared to ¥15,933,984,403.41 in 2022[19]. - The net profit attributable to shareholders for 2023 was ¥2,704,238,767.54, representing a decline of 25.30% from ¥3,620,271,034.96 in 2022[19]. - Basic earnings per share decreased by 25.64% to ¥0.87 in 2023, down from ¥1.17 in 2022[19]. - Total assets at the end of 2023 were ¥39,156,246,864.67, an increase of 2.32% from ¥38,267,625,155.83 at the end of 2022[19]. - The net assets attributable to shareholders increased by 5.22% to ¥24,804,662,320.99 at the end of 2023, compared to ¥23,574,859,468.61 at the end of 2022[19]. - Total revenue for 2023 was ¥15,116,537,003.30, a decrease of 5.13% compared to ¥15,933,984,403.41 in 2022[62]. - Revenue from the pharmaceutical and chemical sector was ¥13,797,766,058.00, accounting for 91.28% of total revenue, down 5.96% from the previous year[62]. - Sales of nutritional products decreased by 9.91% to ¥9,866,822,612.52, representing 65.27% of total revenue[62]. - The gross profit margin for the pharmaceutical and chemical sector was 33.73%, a decline of 4.61 percentage points year-on-year[64]. Cash Flow and Investments - The net cash flow from operating activities increased by 17.38% to ¥5,119,370,863.32 in 2023, compared to ¥4,361,481,083.61 in 2022[19]. - The total cash inflow from investment activities decreased by 50.50% to ¥950,343,311.05, mainly due to a reduction in the redemption of fundraising financial products[85]. - The net cash flow from financing activities decreased by 61.66% to -¥2,053,011,127.17, attributed to a decrease in new borrowings during the reporting period[85]. - The company reported a decrease in cash and cash equivalents by 25.34% to -¥705,271,516.56, primarily due to reduced new borrowings[85]. - The total investment during the reporting period was ¥3,377,423,672.72, a decrease of 32.92% compared to the previous year's investment of ¥5,034,909,624.27[97]. Research and Development - The company has invested over 5% of its revenue in R&D for several consecutive years, establishing a three-tier innovation research and development system[52]. - Research and development expenses rose by 3.36% to ¥887,801,475.02, reflecting ongoing investment in innovation[74]. - The number of R&D personnel increased to 2,803 in 2023, representing a growth of 6.62% compared to 2,629 in 2022[80]. - The company is developing a continuous reaction testing platform and aims to enhance workshop automation and continuous production capabilities[75]. - The R&D efforts include the development of high-safety fat-soluble vitamins and carotenoid formulations, with three products completing large-scale production trials[77]. Market and Industry Position - The company operates in the fine chemical industry, focusing on "Chemicals+" and "Biology+" as core technology platforms[30]. - The company has established itself as one of the world's top four vitamin producers and a leading player in the fine chemical industry in China[37]. - The global methionine production in 2023 is expected to increase by 31.2% year-on-year, with China's output reaching 581,000 tons, representing 34.6% of the global total[32]. - The global flavor and fragrance market size reached 196.4 billion yuan in 2022, with China's market size at 56 billion yuan, accounting for 28.5% of the global market[33]. Corporate Governance - The board of directors has confirmed the accuracy and completeness of the annual report, ensuring no misleading statements or significant omissions[4]. - The company has established a transparent performance evaluation and incentive mechanism linking the compensation of directors and senior management to company performance[134]. - The company has a complete and independent labor, personnel, and compensation management system, with all employees signing labor contracts[137]. - The company ensures timely, accurate, and complete information disclosure to all shareholders[134]. - The company has implemented a performance assessment mechanism to determine the remuneration of directors and senior management based on operational performance[164]. Environmental Compliance - The company maintained compliance with all air and water discharge standards, with no exceedances reported across various pollutants[197]. - The company has established a green development environmental protection concept, focusing on the introduction of green chemistry principles and the production of more environmentally friendly products[200]. - The wastewater treatment system is comprehensive, with separate collection systems for production wastewater, domestic wastewater, initial rainwater, and accident water, ensuring effective pollution control[200]. - The company has successfully renewed pollution discharge permits for multiple subsidiaries, valid until 2028[195]. Employee Engagement and Compensation - The total remuneration for key management personnel in 2023 amounted to ¥26,515.7 million, which includes ¥19,467.7 million for directors, supervisors, and senior management salaries, and performance settlements of ¥4,346.0 million and ¥2,702.0 million for 2021 and 2022 respectively[167]. - The company has a competitive compensation structure, including basic salary, performance pay, and welfare allowances, to improve employee satisfaction and loyalty[175]. - The company plans to enhance talent development through various training programs, focusing on five categories of talent, including core technical and management personnel[177]. - The company has launched a fourth employee stock ownership plan with a purchase amount of RMB 480 million to boost employee engagement and company cohesion[128].